Cargando…
Hormonal impact of the 17α-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer
A series of three dose escalating studies were conducted to investigate the ability of the 17α-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate, to cause maximum suppression of testosterone synthesis when delivered to castrate and noncastrate males with prostate cancer. Study A was a single...
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2004
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409523/ https://www.ncbi.nlm.nih.gov/pubmed/15150570 http://dx.doi.org/10.1038/sj.bjc.6601879 |